JP2020530759A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530759A5 JP2020530759A5 JP2019571705A JP2019571705A JP2020530759A5 JP 2020530759 A5 JP2020530759 A5 JP 2020530759A5 JP 2019571705 A JP2019571705 A JP 2019571705A JP 2019571705 A JP2019571705 A JP 2019571705A JP 2020530759 A5 JP2020530759 A5 JP 2020530759A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- cancer
- fragment
- variant
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 47
- 206010028980 Neoplasm Diseases 0.000 claims 19
- 239000012634 fragment Substances 0.000 claims 18
- 210000001744 T-lymphocyte Anatomy 0.000 claims 14
- 238000000034 method Methods 0.000 claims 13
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims 12
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims 12
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 11
- 108091008874 T cell receptors Proteins 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 10
- 210000001519 tissue Anatomy 0.000 claims 10
- 239000003446 ligand Substances 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 239000013604 expression vector Substances 0.000 claims 6
- 108091023037 Aptamer Proteins 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 230000005847 immunogenicity Effects 0.000 claims 5
- 238000000338 in vitro Methods 0.000 claims 5
- 238000010195 expression analysis Methods 0.000 claims 4
- 230000014509 gene expression Effects 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 3
- 238000003556 assay Methods 0.000 claims 3
- 238000002659 cell therapy Methods 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 238000012163 sequencing technique Methods 0.000 claims 3
- 108091054437 MHC class I family Proteins 0.000 claims 2
- 102000043129 MHC class I family Human genes 0.000 claims 2
- 230000005867 T cell response Effects 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 238000002493 microarray Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000002018 overexpression Effects 0.000 claims 2
- 229920002477 rna polymer Polymers 0.000 claims 2
- 238000010186 staining Methods 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 238000011510 Elispot assay Methods 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 1
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 claims 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 210000000941 bile Anatomy 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 229940022399 cancer vaccine Drugs 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 230000000112 colonic effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 108010028930 invariant chain Proteins 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 239000012931 lyophilized formulation Substances 0.000 claims 1
- 238000004949 mass spectrometry Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 229940038309 personalized vaccine Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000003860 storage Methods 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 238000012070 whole genome sequencing analysis Methods 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023152293A JP2024001045A (ja) | 2017-07-07 | 2023-09-20 | Ｎｓｃｌｃ、ｓｃｌｃ、およびその他のがんをはじめとする肺がんに対する免疫療法で使用するための新規ペプチドおよびペプチド併用 |
| JP2024215092A JP2025038026A (ja) | 2017-07-07 | 2024-12-10 | Ｎｓｃｌｃ、ｓｃｌｃ、およびその他のがんをはじめとする肺がんに対する免疫療法で使用するための新規ペプチドおよびペプチド併用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762529758P | 2017-07-07 | 2017-07-07 | |
| US62/529,758 | 2017-07-07 | ||
| DE102017115301.2 | 2017-07-07 | ||
| DE102017115301 | 2017-07-07 | ||
| PCT/EP2018/067979 WO2019007974A1 (en) | 2017-07-07 | 2018-07-03 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF LUNG CANCER, INCLUDING NSCLC, CPPC AND OTHER CANCERS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023152293A Division JP2024001045A (ja) | 2017-07-07 | 2023-09-20 | Ｎｓｃｌｃ、ｓｃｌｃ、およびその他のがんをはじめとする肺がんに対する免疫療法で使用するための新規ペプチドおよびペプチド併用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020530759A JP2020530759A (ja) | 2020-10-29 |
| JP2020530759A5 true JP2020530759A5 (OSRAM) | 2021-08-19 |
Family
ID=62904428
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019571705A Pending JP2020530759A (ja) | 2017-07-07 | 2018-07-03 | Ｎｓｃｌｃ、ｓｃｌｃ、およびその他のがんをはじめとする肺がんに対する免疫療法で使用するための新規ペプチドおよびペプチド併用 |
| JP2023152293A Pending JP2024001045A (ja) | 2017-07-07 | 2023-09-20 | Ｎｓｃｌｃ、ｓｃｌｃ、およびその他のがんをはじめとする肺がんに対する免疫療法で使用するための新規ペプチドおよびペプチド併用 |
| JP2024215092A Pending JP2025038026A (ja) | 2017-07-07 | 2024-12-10 | Ｎｓｃｌｃ、ｓｃｌｃ、およびその他のがんをはじめとする肺がんに対する免疫療法で使用するための新規ペプチドおよびペプチド併用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023152293A Pending JP2024001045A (ja) | 2017-07-07 | 2023-09-20 | Ｎｓｃｌｃ、ｓｃｌｃ、およびその他のがんをはじめとする肺がんに対する免疫療法で使用するための新規ペプチドおよびペプチド併用 |
| JP2024215092A Pending JP2025038026A (ja) | 2017-07-07 | 2024-12-10 | Ｎｓｃｌｃ、ｓｃｌｃ、およびその他のがんをはじめとする肺がんに対する免疫療法で使用するための新規ペプチドおよびペプチド併用 |
Country Status (18)
| Country | Link |
|---|---|
| US (47) | US10472402B2 (OSRAM) |
| EP (2) | EP3648790A1 (OSRAM) |
| JP (3) | JP2020530759A (OSRAM) |
| KR (2) | KR20250007011A (OSRAM) |
| CN (2) | CN119080881A (OSRAM) |
| AU (3) | AU2018297578C1 (OSRAM) |
| BR (1) | BR112019028070A2 (OSRAM) |
| CA (1) | CA3068852A1 (OSRAM) |
| CL (4) | CL2020000020A1 (OSRAM) |
| CO (1) | CO2020001141A2 (OSRAM) |
| CR (4) | CR20210169A (OSRAM) |
| IL (2) | IL271895A (OSRAM) |
| MX (2) | MX2019015879A (OSRAM) |
| MY (1) | MY198706A (OSRAM) |
| PE (1) | PE20200693A1 (OSRAM) |
| PH (1) | PH12020500051A1 (OSRAM) |
| SG (1) | SG11201913302SA (OSRAM) |
| TW (1) | TW201906859A (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20210169A (es) | 2017-07-07 | 2021-06-10 | Immatics Biotechnologies Gmbh | NUEVOS PÉPTIDOS Y NUEVAS COMBINACIONES DE PÉPTIDOS PARA EL USO DE LA INMUNOTERAPIA CONTRA EL CÁNCER DE PULMÓN, INCLUYENDO EL NSCLC, EL SCLC Y OTROS CÁNCERES (Divisional 2020-0059) |
| WO2019007974A1 (en) * | 2017-07-07 | 2019-01-10 | Immatics Biotechnologies Gmbh | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF LUNG CANCER, INCLUDING NSCLC, CPPC AND OTHER CANCERS |
| CN111732629B (zh) * | 2020-06-19 | 2022-05-03 | 完美（广东）日用品有限公司 | 一种寡肽、减肥组合物及制备方法和应用 |
| CN114019165B (zh) * | 2022-01-05 | 2022-04-01 | 首都医科大学附属北京妇产医院 | 多肽芯片或试剂盒及其在诊断非小细胞肺癌中的应用 |
| CN115785212B (zh) * | 2022-06-10 | 2024-08-30 | 河北博海生物工程开发有限公司 | 肺癌特异性分子靶标03及其用途 |
| CN116879433A (zh) * | 2023-07-05 | 2023-10-13 | 国纳之星(上海)纳米科技发展有限公司 | 肺癌患患者特异性生物标志组合物及其用途 |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| IE53176B1 (en) | 1978-12-22 | 1988-08-17 | Biogen Nv | Recombinant dna molecules and their method of production |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
| US4897445A (en) | 1986-06-27 | 1990-01-30 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide bond |
| WO1994029347A1 (en) | 1993-06-03 | 1994-12-22 | Therapeutic Antibodies Inc. | Antibody fragments in therapy |
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| WO1997026328A1 (en) | 1996-01-17 | 1997-07-24 | Imperial College Innovations Limited | Immunotherapy using cytotoxic t lymphocytes (ctl) |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| AU3389500A (en) | 1999-03-02 | 2000-09-21 | Ludwig Institute For Cancer Research | Cloning of cdna of mage's 5, 8, 9 and 11 and their uses in diagnosis of cancer |
| WO2001031034A1 (en) | 1999-10-25 | 2001-05-03 | Millennium Pharmaceuticals, Inc. | 27875 a human adam-ts homolog |
| EP1118860A1 (en) | 2000-01-21 | 2001-07-25 | Rijksuniversiteit te Leiden | Methods for selecting and producing T cell peptide epitopes and vaccines incorporating said selected epitopes |
| US6934639B1 (en) | 2000-02-25 | 2005-08-23 | Wyeth | Methods for designing agents that interact with MMP-13 |
| US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
| JP2004503213A (ja) | 2000-03-27 | 2004-02-05 | テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド | １本鎖クラスｉ主要組織適合性複合体、それをコードする構築物およびそれを生成する方法 |
| AUPQ776100A0 (en) * | 2000-05-26 | 2000-06-15 | Australian National University, The | Synthetic molecules and uses therefor |
| AU2001275246B2 (en) | 2000-06-05 | 2006-06-29 | Altor Bioscience Corporation | T cell receptor fusions and conjugates and methods of use thereof |
| US7919467B2 (en) | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| US20040053822A1 (en) | 2000-12-11 | 2004-03-18 | John Fikes | Inducing cellular immune responses to mage2/3 using peptide and nucleic acid compositions |
| WO2003008537A2 (en) | 2001-04-06 | 2003-01-30 | Mannkind Corporation | Epitope sequences |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| AU2003216341A1 (en) | 2002-02-20 | 2003-09-09 | Dyax Corporation | Mhc-peptide complex binding ligands |
| DE60235524D1 (de) | 2002-04-17 | 2010-04-15 | Deutsches Krebsforsch | Verfahren zum Screening einer Substanz zur Modulierung der wnt -Signalkaskade. |
| NZ539225A (en) | 2002-10-09 | 2006-09-29 | Avidex Ltd | Single chain recombinant T cell receptors |
| NZ539226A (en) | 2002-11-09 | 2008-09-26 | Medigene Ltd | T cell receptor display |
| GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| KR100568755B1 (ko) | 2003-04-03 | 2006-04-07 | 주식회사 리젠 바이오텍 | Ｙｈ 모티프를 포함하는 펩타이드를 유효성분으로함유하는 혈관신생 억제제 |
| DE102005013846A1 (de) * | 2005-03-24 | 2006-10-05 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
| DE102005041616B4 (de) | 2005-09-01 | 2011-03-17 | Johannes-Gutenberg-Universität Mainz | Melanom-assoziierte MHC Klasse I assoziierte Oligopeptide und für diese kodierende Polynukleotide und deren Verwendungen |
| ES2341802T3 (es) | 2005-09-05 | 2010-06-28 | Immatics Biotechnologies Gmbh | Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii. |
| EP1951891B1 (en) | 2005-11-14 | 2012-02-15 | Université Laval | Cancer antigen mage-a9 and uses thereof |
| EP2125005B1 (en) | 2007-03-26 | 2015-04-08 | Academisch Ziekenhuis Leiden h.o.d.n. LUMC | Prame derived peptides and immunogenic compositions comprising these |
| US8566755B2 (en) | 2007-11-26 | 2013-10-22 | Macronix International Co., Ltd. | Method of correcting photomask patterns |
| US20090263574A1 (en) | 2008-04-21 | 2009-10-22 | Quinn Daniel E | Method of restoring an article |
| SI2294066T1 (sl) | 2008-04-28 | 2014-12-31 | Janssen Pharmaceutica N.V. | Benzoimidazoli kot inhibitorji prolil-hidroksilaze |
| NO2119726T3 (OSRAM) | 2008-05-14 | 2015-05-23 | ||
| EP2337795A2 (en) | 2008-10-01 | 2011-06-29 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| GB0910725D0 (en) | 2009-06-22 | 2009-08-05 | Heptares Therapeutics Ltd | Mutant proteins and methods for producing them |
| CA2793383A1 (en) | 2010-03-16 | 2011-09-22 | Adapta Medical, Inc. | Catheter reservoir seals |
| GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| CN103108887A (zh) | 2010-07-22 | 2013-05-15 | 葛兰素史密丝克莱恩生物有限公司 | 新的抗原结合蛋白 |
| US8710014B2 (en) * | 2010-10-08 | 2014-04-29 | Proteapex Therapeutics Llc | Compositions and methods for inhibition of MMP13:MMP-substrate interactions |
| CA2816225A1 (en) | 2010-10-26 | 2012-05-03 | Technion Research & Development Foundation Ltd. | Antibodies which bind soluble t-cell receptor ligands |
| WO2013057586A1 (en) | 2011-10-19 | 2013-04-25 | Oslo Universitetssykehus Hf | Compositions and methods for producing soluble t - cell receptors |
| CA2860307A1 (en) | 2011-12-21 | 2013-06-27 | Integrated Diagnostics, Inc. | Selected reaction monitoring assays |
| HK1206601A1 (en) * | 2012-04-02 | 2016-01-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
| US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| WO2014071978A1 (en) | 2012-11-08 | 2014-05-15 | Roche Diagnostics Gmbh | Nucleic acids encoding chimeric polypeptides for library screening |
| EP2808392A1 (en) | 2013-05-28 | 2014-12-03 | Rheinische Friedrich-Wilhelms-Universität Bonn | Aptamers and use of the aptamers in the diagnosis and treatment of cancer |
| US10188712B2 (en) | 2013-07-30 | 2019-01-29 | Biontech Ag | Tumor antigens for determining cancer therapy |
| TWI775117B (zh) | 2013-08-05 | 2022-08-21 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（二） |
| GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| WO2016179006A1 (en) | 2015-05-01 | 2016-11-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating t cells and t cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood |
| IL302102A (en) * | 2015-05-20 | 2023-06-01 | Dana Farber Cancer Inst Inc | shared neoantigens |
| US20170136108A1 (en) | 2015-08-28 | 2017-05-18 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| GB201517538D0 (en) | 2015-10-05 | 2015-11-18 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
| GB201520559D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520579D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201601136D0 (en) | 2016-01-21 | 2016-03-09 | Mörgelin Matthias And Abdillahi Suado M | Novel polypeptides and medical uses thereof |
| WO2017150681A1 (ja) * | 2016-03-03 | 2017-09-08 | 東亞合成株式会社 | シグナルペプチドを指標にした筋萎縮性側索硬化症の診断方法 |
| AU2017254477A1 (en) * | 2016-04-18 | 2018-11-01 | Jennifer G. ABELIN | Improved HLA epitope prediction |
| EP3725327A3 (en) * | 2017-04-10 | 2021-01-20 | Immatics Biotechnologies GmbH | Peptides and combination thereof for use in the immunotherapy against cancers |
| KR20190137858A (ko) * | 2017-04-10 | 2019-12-11 | 이매틱스 바이오테크놀로지스 게엠베하 | 백혈병 및 다른 암에 대한 면역요법에 사용하기 위한 펩티드 및 펩티드의 조합 |
| AU2018298422B2 (en) * | 2017-07-04 | 2023-04-06 | CureVac SE | Novel nucleic acid molecules |
| WO2019007974A1 (en) | 2017-07-07 | 2019-01-10 | Immatics Biotechnologies Gmbh | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF LUNG CANCER, INCLUDING NSCLC, CPPC AND OTHER CANCERS |
| CR20210169A (es) | 2017-07-07 | 2021-06-10 | Immatics Biotechnologies Gmbh | NUEVOS PÉPTIDOS Y NUEVAS COMBINACIONES DE PÉPTIDOS PARA EL USO DE LA INMUNOTERAPIA CONTRA EL CÁNCER DE PULMÓN, INCLUYENDO EL NSCLC, EL SCLC Y OTROS CÁNCERES (Divisional 2020-0059) |
| CN112512538A (zh) * | 2018-05-18 | 2021-03-16 | 国家儿童医疗中心 | 改进的靶向t细胞疗法 |
| TW202028224A (zh) * | 2018-09-17 | 2020-08-01 | 德商英麥提克生物技術股份有限公司 | B*44限制肽在抗癌免疫治療的用途和相關方法 |
-
2018
- 2018-07-03 CR CR20210169A patent/CR20210169A/es unknown
- 2018-07-03 SG SG11201913302SA patent/SG11201913302SA/en unknown
- 2018-07-03 KR KR1020247041050A patent/KR20250007011A/ko active Pending
- 2018-07-03 CN CN202411243812.9A patent/CN119080881A/zh active Pending
- 2018-07-03 CA CA3068852A patent/CA3068852A1/en active Pending
- 2018-07-03 MY MYPI2019007606A patent/MY198706A/en unknown
- 2018-07-03 PE PE2020000025A patent/PE20200693A1/es unknown
- 2018-07-03 KR KR1020207001447A patent/KR20200026898A/ko not_active Ceased
- 2018-07-03 EP EP18740138.5A patent/EP3648790A1/en active Pending
- 2018-07-03 BR BR112019028070-7A patent/BR112019028070A2/pt not_active Application Discontinuation
- 2018-07-03 JP JP2019571705A patent/JP2020530759A/ja active Pending
- 2018-07-03 CR CR20210167A patent/CR20210167A/es unknown
- 2018-07-03 EP EP23216393.1A patent/EP4316597A3/en active Pending
- 2018-07-03 AU AU2018297578A patent/AU2018297578C1/en not_active Expired - Fee Related
- 2018-07-03 CN CN201880041940.1A patent/CN110785183B/zh active Active
- 2018-07-03 CR CR20200059A patent/CR20200059A/es unknown
- 2018-07-03 TW TW107122872A patent/TW201906859A/zh unknown
- 2018-07-03 CR CR20210168A patent/CR20210168A/es unknown
- 2018-07-03 MX MX2019015879A patent/MX2019015879A/es unknown
-
2019
- 2019-04-18 US US16/387,610 patent/US10472402B2/en active Active
- 2019-09-26 US US16/584,022 patent/US10597434B2/en active Active
- 2019-12-20 MX MX2022005897A patent/MX2022005897A/es unknown
-
2020
- 2020-01-03 CL CL2020000020A patent/CL2020000020A1/es unknown
- 2020-01-06 PH PH12020500051A patent/PH12020500051A1/en unknown
- 2020-01-07 IL IL271895A patent/IL271895A/en unknown
- 2020-01-29 US US16/776,244 patent/US10711048B2/en active Active
- 2020-01-31 CO CONC2020/0001141A patent/CO2020001141A2/es unknown
- 2020-05-01 US US16/864,897 patent/US10836806B2/en not_active Expired - Fee Related
-
2021
- 2021-07-09 US US17/371,826 patent/US11279740B2/en active Active
- 2021-07-09 US US17/371,871 patent/US11279741B2/en active Active
- 2021-07-16 US US17/377,867 patent/US11292821B2/en active Active
- 2021-07-16 US US17/377,905 patent/US11261224B2/en active Active
- 2021-09-02 US US17/465,597 patent/US11352401B1/en active Active
- 2021-09-17 US US17/477,869 patent/US11370817B2/en active Active
- 2021-12-23 US US17/561,051 patent/US11414470B2/en active Active
-
2022
- 2022-01-07 US US17/570,943 patent/US11407798B2/en active Active
- 2022-01-14 US US17/576,714 patent/US11618774B2/en active Active
- 2022-01-21 US US17/581,260 patent/US11414471B2/en active Active
- 2022-01-28 US US17/587,387 patent/US11414472B2/en active Active
- 2022-02-04 US US17/665,199 patent/US11414473B2/en active Active
- 2022-02-11 US US17/669,601 patent/US11427622B2/en active Active
- 2022-02-18 US US17/674,910 patent/US11459365B2/en active Active
- 2022-02-25 US US17/681,107 patent/US11459366B2/en active Active
- 2022-03-04 US US17/687,307 patent/US11498948B2/en active Active
- 2022-03-11 US US17/693,316 patent/US11479589B2/en active Active
- 2022-03-16 CL CL2022000641A patent/CL2022000641A1/es unknown
- 2022-03-16 CL CL2022000642A patent/CL2022000642A1/es unknown
- 2022-05-16 AU AU2022203259A patent/AU2022203259B2/en not_active Ceased
- 2022-06-17 US US17/843,733 patent/US12195507B2/en active Active
- 2022-07-08 US US17/860,840 patent/US12240878B2/en active Active
- 2022-07-08 US US17/860,600 patent/US12240877B2/en active Active
- 2022-07-08 US US17/860,827 patent/US12195508B2/en active Active
- 2022-07-08 US US17/860,803 patent/US20220363729A1/en not_active Abandoned
- 2022-07-22 US US17/871,724 patent/US12275768B2/en active Active
- 2022-07-22 US US17/871,615 patent/US12195509B2/en active Active
- 2022-07-29 US US17/877,535 patent/US20230051523A1/en not_active Abandoned
- 2022-07-29 US US17/877,515 patent/US12247057B2/en active Active
- 2022-08-12 US US17/819,470 patent/US12281146B2/en active Active
- 2022-08-12 US US17/886,752 patent/US20230002461A1/en not_active Abandoned
- 2022-08-18 US US17/820,824 patent/US20230174602A1/en not_active Abandoned
- 2022-08-18 US US17/820,821 patent/US12297245B2/en active Active
- 2022-08-26 US US17/822,657 patent/US20230021673A1/en not_active Abandoned
- 2022-08-26 US US17/822,653 patent/US20230094553A1/en not_active Abandoned
- 2022-09-02 US US17/929,344 patent/US20230094286A1/en not_active Abandoned
- 2022-09-02 US US17/929,347 patent/US20230116279A1/en not_active Abandoned
- 2022-09-09 US US17/930,891 patent/US20230035702A1/en not_active Abandoned
- 2022-09-19 US US17/933,353 patent/US20230109584A1/en not_active Abandoned
- 2022-09-19 US US17/933,298 patent/US20230043654A1/en not_active Abandoned
- 2022-09-23 US US17/934,663 patent/US20230192791A1/en not_active Abandoned
- 2022-09-23 US US17/934,747 patent/US20230042253A1/en not_active Abandoned
- 2022-09-23 US US17/934,673 patent/US20230046543A1/en not_active Abandoned
-
2023
- 2023-04-07 US US18/297,076 patent/US20230279066A1/en active Pending
- 2023-05-10 US US18/314,878 patent/US20230340046A1/en active Pending
- 2023-07-04 AU AU2023204282A patent/AU2023204282A1/en not_active Abandoned
- 2023-07-09 IL IL304321A patent/IL304321A/en unknown
- 2023-08-11 US US18/448,614 patent/US20230382964A1/en active Pending
- 2023-09-20 JP JP2023152293A patent/JP2024001045A/ja active Pending
-
2024
- 2024-02-21 CL CL2024000530A patent/CL2024000530A1/es unknown
- 2024-12-10 JP JP2024215092A patent/JP2025038026A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021168652A5 (OSRAM) | ||
| JP2018529320A5 (OSRAM) | ||
| JP2019506838A5 (OSRAM) | ||
| JP2019502360A5 (OSRAM) | ||
| JP2019510465A5 (OSRAM) | ||
| JP2018510628A5 (OSRAM) | ||
| JP2018509135A5 (OSRAM) | ||
| JP2018519243A5 (OSRAM) | ||
| JP2019511214A5 (OSRAM) | ||
| JP2018536383A5 (OSRAM) | ||
| JP2024099580A5 (OSRAM) | ||
| JP2024041841A5 (OSRAM) | ||
| JP2018511321A5 (OSRAM) | ||
| JP2018518937A5 (OSRAM) | ||
| JP2018520653A5 (OSRAM) | ||
| JP2020530759A5 (OSRAM) | ||
| JP2017525336A5 (OSRAM) | ||
| JP2018521641A5 (OSRAM) | ||
| JP2017502076A5 (OSRAM) | ||
| JP2018518956A5 (OSRAM) | ||
| RU2017137142A (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака | |
| JP2020516681A5 (OSRAM) | ||
| JP2017524337A5 (OSRAM) | ||
| JP2021101700A5 (OSRAM) | ||
| JPWO2019162110A5 (OSRAM) |